AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Exact Sciences Corp. announced breakthrough results from the ALTUS study, demonstrating superior early detection of liver cancer with its Oncoguard Liver blood test. The study found that the test delivered seven times greater sensitivity for very early-stage hepatocellular carcinoma (HCC) compared to the standard of care. The ALTUS study is the largest prospective trial of a blood test for liver cancer surveillance in the United States, reflecting the racial and ethnic diversity of high-risk groups.

Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet